We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

By LabMedica International staff writers
Posted on 13 Jun 2025

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. More...

In emergency departments (EDs), the absence of reliable and objective early risk assessment tools often leads clinicians to treat a broad range of patients as potentially septic. While this cautious approach is understandable in the high-pressure ED setting, it frequently results in unnecessary and non-beneficial treatments for individuals unlikely to have sepsis. In addition to being a clinical challenge, sepsis also poses a significant financial burden. Hospitals with more than 500 beds may face annual sepsis-related expenditures surpassing USD34 million. A major real-world study now shows that a sepsis diagnostic tool can lower the relative rate of sepsis mortality, reduce hospital stay duration, and improve resource utilization in the ED.

Cytovale’s (San Francisco, CA, USA) IntelliSep stands out as the first and only FDA-cleared diagnostic tool designed to support early detection of sepsis in emergency settings. It uses a standard blood sample and delivers results in approximately eight minutes. This rapid turnaround allows healthcare professionals to assess sepsis risk before traditional clinical symptoms become apparent, enhancing their ability to prioritize care for those in critical need. The integration of this fast diagnostic test with a structured workflow has resulted in what researchers have referred to as a “game-changing model” for healthcare systems across the country. The study tracked over 12,000 patients across a 12-month period at a 900-bed inpatient acute care hospital and Level 1 trauma center, where IntelliSep was used within a nurse-led sepsis triage program aimed at quickly identifying and managing patients at the highest risk.

The findings, detailed in the journal Healthcare, reveal a 39% relative reduction in mortality among sepsis patients, while mortality among non-sepsis patients remained unchanged—highlighting IntelliSep’s role in improving targeted triage. Additionally, the average hospital stay for patients with sepsis was shortened by 0.76 days, signaling benefits for both patient flow and cost management. The research also noted a 40% drop in blood culture use for patients deemed low-risk and an 8% rise in usage among high-risk individuals. These patterns demonstrate IntelliSep’s capacity to enhance diagnostic accuracy and better align testing with patient risk levels.

"This is more than an innovation – it's a paradigm shift in how health systems are managing sepsis," said Dr. Hollis O'Neal, Medical Director of Research at OLOLRMC, the acute care facility which implemented IntelliSep. "For decades, sepsis mortality rates have remained stagnant because we've lacked a fast, reliable way to catch sepsis early. This study proves that with speed, objectivity and accuracy at the point of triage, we can change outcomes before antibiotics are given or ICU beds are needed. That's where real transformation begins."

Related Links:
Cytovale


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette
Accumax Smart Series
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.